[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637987":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":44,"collaborators":18,"id":46,"slug":18,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":18,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":18,"overallStatus":31,"whyStopped":18,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University of Minnesota","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Elevated Pacemaker Rate","EXPERIMENTAL","CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.",[13],"Other: Pacemaker Rate",[15],{"type":6,"name":16,"description":11,"armGroupLabels":17,"otherNames":18},"Pacemaker Rate",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Valmiki Maharaj","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Meghan Muscala","CONTACT","612-626-5863","payne324@umn.edu",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Minneapolis","Minnesota","55455","United States",{"type":37,"coordinates":38},"Point",[39,40],-93.26384,44.97997,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},{"type":45,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100637987",false,"NCT07583823","Elevated Rate Pacing of Cardiac Amyloidosis","Inclusion Criteria:\n\n* Adults 18 and older\n* Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: \"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee\n* Implanted Cardiac Pacemaker (+\u002F- Defibrillator)\n* Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation\n* Non-dilated left ventricle by echocardiography\n* Ability to provide written consent\n* English Speaking\n\nExclusion Criteria:\n\n* Paced QRS duration of \\>150 ms (indicator for pacing mediated dyssynchrony)\n* Dilated left ventricle","ALL","18 Years",{"count":54,"type":55},10,"ESTIMATED","INTERVENTIONAL",[58],"NA","This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.",[61,62],"Cardiac Amyloidosis","Pacemaker","2026-05-06",{"date":65,"type":66},"2026-05-13","ACTUAL",{"date":68,"type":66},"2025-10-10",{"date":70,"type":55},"2026-10-10",{"name":5,"class":6},1]